AMRX Q2 2019 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q2 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$405M-2.2% YoY

Gross Profit

$105M26.0% margin

Operating Income

-$19M-4.7% margin

Net Income

-$17M-4.2% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

-9.3%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

-$41M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$4.3B

Total Liabilities

$3.5B

Stockholders' Equity

$460M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$405M	$414M	-2.2%
Gross Profit	$105M	$178M	-41.0%
Operating Income	-$19M	-$181M	+89.6%
Net Income	-$17M	-$219M	+92.3%

Revenue Segments

Levothyroxine Sodium

$46M35%

Rytary Family

$33M25%

Diclofenac Sodium Gel

$25M19%

Epinephrine Auto-Injector Family (Generic Adrenaclick)

$16M12%

Yuvafem-Estradiol

$14M10%